We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued an emergency use authorization (EUA) for the anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate, clearing the way for HHS to distribute millions of doses for COVID-19 patients. Read More
Manufacturers need to provide two-week updates on any supply issues during the COVID-19 emergency and going forward, the FDA said in a new straight-to-final guidance. Read More
The FDA has updated its guidance on conducting clinical trials during the COVID-19 pandemic with an extensive Q&A section, including a long list of factors to consider when deciding the status of ongoing trials and ones soon to be initiated. Read More
